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Objective:  To  describe  gender  differences  in  injection  and  sexual  risks  behaviours,  and  human  immuno-
deﬁciency  virus  (HIV)  and  hepatitis  C (HCV)  prevalence  among  injecting  drug  users  (IDU)  in  Catalonia,
Spain.
Methods:  Cross-sectional  studies  in  2008–2009  (n  = 748) and  2010–2011  (n  = 597)  in  the  network  of
harm  reduction  centres.  Face  to face  interviews  were  conducted  and  oral  ﬂuid  samples  were  collected  to
estimate  HIV/HCV  prevalence.
Results:  Female  were  more  likely  than  male  IDU to have  had a steady  sexual  partner  (68.2% versus  44.9%),
to  have  had an  IDU  steady  sexual  partner  (46.6% versus  15.1%)  and  to  have  exchanged  sex for  money
or  drugs  in  the  last  6 months  (25.5%  versus  2.3%).  There  were  no  gender  differences  in  injecting  risk
behaviours.  HIV  prevalence  was 38.7%  (91/235)  in  women  and  31.5%  (347/1103)  in  men  (p =  0.031).  HIV
prevalence  among  female  IDU  who  reported  having  exchange  sex for money  or drugs  was  53.3% (32/60).
The  prevalence  of  HCV  was 67.4%  (159/236)  and  73.6%  (810/1101)  in female  and  male  IDU,  respectively
(p  = 0.053).  After  adjustment  by immigrant  status,  age  and  years  of injection,  differences  among  HIV/HCV
prevalence  by gender  were  not  signiﬁcant.
Conclusions:  This  study  demonstrated  differences  in  sexual  risk  behaviours  between  male  and  female  IDU,
but failed  to ﬁnd  gender  differences  in  injecting  risk  behaviours.  Apart  from  that,  the  higher  prevalence
of  HIV  among  women  than  among  men,  together  with  a  lower  prevalence  of  HCV,  provides  evidence
that  sexual  transmission  of HIV is  important  among  female  IDU.  Additional  studies  are  needed  to  analyze
in-depth  these  speciﬁc  risk  factors  for women  in order  to develop  appropriate  prevention  and  health
education  programs.
©  2012  SESPAS.  Published  by Elsevier  España,  S.L.  All rights  reserved.
Diferencias  de  género  en  los  comportamientos  de  riesgo  de  VIH  entre  los
usuarios  de  drogas  intravenosas  en  Catalun˜a,  Espan˜a
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Objetivo:  Describir  diferencias  de  género  en  las conductas  de  riesgo  sexual  y parenteral,  y en  la  prevalencia
de  los virus  de la  inmunodeﬁciencia  humana  (VIH)  y de la hepatitis  C (VHC)  en  los  usuarios  de  drogas  por
vía  parenteral  (UDVP)  en  Catalun˜a.
Métodos:  Estudios  transversales  realizados  en  2008-09  (n  = 748)  y  2010-11  (n  = 597) en  centros  de  reduc-suarios de drogas por vía parenteral
buso de sustancias
onductas de riesgo
ción  de  dan˜os.  Se  realizaron  entrevistas  y  se recogieron  muestras  de ﬂuido  oral  para  estimar  la prevalencia
del VIH  y del  VHC.
Resultados:  En relación  a  las  conductas  sexuales  de  los  últimos  6 meses,  un mayor  porcentaje  de  mujeres
que  de  hombres  declaró  tener  una  pareja  estable  (68,2%  frente  a 44,9%),  declaró  tener  una  pareja  estable
también  UDVP  (46,6%  frente  a 15,1%)  y aﬁrmó  haber  mantenido  relaciones  sexuales  comerciales  (25,5%
frente  a  2,3%).  No  se  observaron  diferencias  según  género  en  las conductas  de  riesgo  relacionadas  con
la inyección.  La  prevalencia  global  del  VIH  fue  del  38,7%  (91/235)  en  las  mujeres  y  del 31,5%  (347/1103)
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en  los  hombres  (p = 0,031),  con  una  prevalencia  del  53,3%  (32/60)  en  las  mujeres  que  declararon  tener
relaciones  sexuales  comerciales.  La prevalencia  del VHC  en  las  mujeres  fue  ligeramente  inferior  a  la obser-
vada  en los hombres:  67,4%  (159/236)  y  73,6%  (810/1101),  respectivamente  (p = 0,053).  Al  ajustar  por  ser
o  no  inmigrante,  edad  y an˜os  de  inyección,  las diferencias  en  la  prevalencia  de  ambos  virus  no  resultaron
estadísticamente  signiﬁcativas.
Conclusiones:  El  estudio  muestra  diferencias  de  género  en  las  conductas  de  riesgo  sexual  de los  UDVP,
pero  no  en  las  conductas  de riesgo  parenteral.  Estos  datos,  junto  con  una  mayor  prevalencia  del  VIH  en las
mujeres  y una prevalencia  inferior  en  relación  al VHC, ponen  de  maniﬁesto  la  relevancia  de  la  transmisión
sexual del  VIH  en este  colectivo.  Serán  necesarios  estudios  adicionales  para  explorar  en  profundidad  estos
factores  de  riesgo  especíﬁcos  en  las  mujeres  UDVP  y  poder  desarrollar  programas  de  prevención  adaptados
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Women  who inject drugs have substantially different needs and
ace higher risk of disease and violence than do male injecting drug
sers (IDU).1 Regarding HIV infection, gender has emerged as an
mportant factor in both injection related and sexual risk taking
n IDU in different parts of the world, with female IDU more likely
han males to take risks that may  lead to HIV infection.2–5 In partic-
lar, female IDU are more likely than males to have a sexual partner
ho also injects drugs6–9 as well as to engage in sex for money or
rugs,2,7,10 both factors previously associated with a greater risk
f HIV transmission.11,12 Despite this, many harm reduction pro-
rams do not respond to the speciﬁc needs of female IDU, such
s a reproductive health care. At the same time, female IDU may
lso encounter barriers in accessing services because of house-
old responsibilities, lack of family support, and lack of ﬁnancial
esources.13
Recent available data among IDU in Europe showed a prevalence
f HIV of 13.6% among men  and 21.5% among women. In contrast to
IV, prevalence for hepatitis C virus (HCV) was very similar in male
nd female IDU: 58.1% and 56.4%, respectively.14 The contrasting
ndings for HIV and HCV could suggest that the large gender dif-
erence in HIV prevalence is probably due to differences in sexual
isks in males and females, in line with a previous European mul-
icenter study in which sexual behaviour emerged as the strongest
redictor of HIV in this population.15
The Spanish HIV epidemic has been characterized by extremely
igh rates in IDU from the mid  1980s to date,16 and previous
tudies have pointed to a higher HIV prevalence and incidence
mong female than male IDU.17 Few studies in Spain have been
onducted on gender differences in risk behaviour among IDU.
n understanding of these differences will have major implica-
ions for designing preventive programmes and interventions. This
tudy aims to describe gender differences in injection and sexual
isks behaviours, and HIV/HCV prevalence among IDU in Catalonia
Spain).
aterial and methods
tudy design
As part of the Integrated HIV/STI Surveillance System (SIVES),18
iennial bio-behavioural surveillance surveys among IDU are
mplemented in Catalonia. In particular, two cross-sectional stud-
es were carried out in 2008–2009 and 2010–2011 in the network
f harm reduction centres. These centres provide needle exchange
rograms, supervised injecting facilities, and “outreach programs”
eﬁned as an approach for contacting drug users in their local
eighbourhoods and providing them with education, risk reduc-
ion counselling and the means to change their risk behaviours
elated to HIV. The data from both surveys were combined in orderESPAS.  Publicado  por Elsevier  España,  S.L.  Todos  los  derechos  reservados.
to increase the number of women IDU and to have greater statistical
power.
Participants
After collecting data on the number and characteristics of
clients contacted by harm reduction centres in the previous year,
a convenience stratiﬁed sample of 748 and 760 IDU was selected,
respectively, according to the type of centre and country of ori-
gin using proportional allocation for each study. For the purpose
of the study, participants who  admitted having been completed
a questionnaire in the previous survey were excluded to ensure
independence of samples (N = 163). The total sample included in
the analysis was  1345. Individuals who reported having injected
in the previous six months and who attended these centres were
eligible to take part. Those who agreed to participate signed the
informed consent document and received 24D .
Measures
Face to face interviews were conducted by trained interview-
ers using an anonymous structured questionnaire adapted from
that of the World Health Organization.19 The questionnaire was
translated into Spanish, Romanian, Russian, English, and French,
and included questions on sociodemographic characteristics (coun-
try of origin, age, sex, education level, occupational status, where
they live, in treatment for drug addiction), drug use (frequency of
injection, sharing of syringes, drugs used), sexual practices (com-
mercial sex work, use of condoms with steady and casual partners),
access to free condoms, knowledge of HIV and HCV status and previ-
ous history of sexually transmitted infections (STI). The majority of
questions regarding behaviour referred to the preceding 6 months.
Oral ﬂuid samples were also taken anonymously to determine
the prevalence of HIV and HCV infection. Anti-HIV antibodies were
detected in oral ﬂuid using Genscreen HIV1-2 v.2.0 from BIORAD
according to the manufacturer’s instructions (sensitivity = 98.5%;
speciﬁcity = 100%)20; anti-HCV antibodies were detected using HCV
3.0 SAVe ELISA (sensitivity = 86.7%; speciﬁcity = 100%).21
Ethical approval was obtained from the Hospital Universitari
Germans Trias i Pujol Ethics Committee. Details of the method have
been reported elsewhere.22
Statistical analysis
Gender differences were examined using chi-square tests
and the Fisher’s exact test for categorical variables and the
Mann–Whitney test for continuous variables. Logistic regression
models were used to determine factors associated with being
female after adjustment for some possible confounding factors such
as the age (less than 35 or more), immigrant status (yes/no), and
years of injection (less than 5 years or more). Statistical signiﬁcance
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Table 1
Socio-demographic and patterns of drug use characteristics by gender.
Male IDUn (%) Female IDUn (%) p-valuea
Median age (IQR) 36 (31–42) 35 (28–42) 0.027
Immigrant 494 (44.5) 63 (26.7) <0.0001
Educational level: primary or less 277 (25.1) 52 (22.0) 0.322
Living  in occupied houses (squatters)b 115 (10.4) 39 (16.5) 0.007
Homelessb 263 (23.7) 38 (16.1) 0.011
Ever  in prison 754 (68.1) 121 (51.3) <0.0001
Employmentb 245 (22.3) 34 (14.5) 0.008
Receiving a pensionb,c 205 (18.6) 66 (28.1) 0.001
In  treatment for drug addiction 542 (48.9) 129 (54.9) 0.206
Frequency of injection: dailyb 546 (49.2) 105 (44.5) 0.186
Injection of heroineb 898 (81.3) 185 (78.7) 0.354
Injection of cocaineb 748 (67.8) 159 (67.7) 0.978
Injection of speedballc 688 (62.5) 105 (45.1) <0.0001
Median  years of injection (IQR) 15 (7–22) 13 (6–21) 0.097
IDU, injecting drug users; IQR, interquartile range.
us var
.
w
v
R
i
T
u
(
(
2
t
v
h
t
l
s
1
6
w
s
p
s
T
I
Ia Chi-square tests for categorical variables and Mann–Whitney tests for continuo
b Last 6 months.
c Retirement pension or incapacity beneﬁt or social fund community care grants
as set at p < 0.05. The analyses were performed using SPSS
ersion 17.
esults
A total of 748 (17.8% women) and 597 (17.3% women) IDU were
ncluded in the analysis in 2008–2009 and 2010–2011, respectively.
he main socio-demographic characteristics and patterns of drug
se are presented in Table 1. Overall, female IDU were younger
median age 35 versus 36 years), less likely to be an immigrant
26.7% versus 44.5%) and to have an employment (14.5% versus
2.3%), and more likely to report living in occupied houses (squat-
ers) (16.5% versus 10.4%) and to receive any kind of pension (28.1%
ersus 18.6%) compared to male. More men  than women  reported
aving injected speedball in the last 6 months (62.5% versus 45.1%).
There were no gender differences in injecting risk behaviours in
his sample. Regarding sexual risk behaviours, female were more
ikely than male IDU to have had a steady sexual partner (68.2% ver-
us 44.9%), to have had an IDU steady sexual partner (46.6% versus
5.1%) and to have exchanged sex for money or drugs in the last
 months (25.5% versus 2.3%). In contrast, the proportion of men
ith casual partners was higher than among women  (38.6% ver-
us 20.8%). In the last episode of sexual intercourse with a steady
artner, fewer female IDU used condoms than male (27.3% ver-
us 40.4%). After controlling for age, immigrant status and years of
able 2
njecting and sexual risk behaviours by gender.
Male IDUn (%) Female ID
Ever sharing syringes 550 (49.7) 131 (5
Accepted syringesc 176 (16.0) 42 (1
Passed on syringesc 191 (17.8) 53 (2
Front/backloadingc 517 (48.3) 110 (4
Sharing other injecting equipmentc 553 (51.9) 108 (4
Steady sexual partnerc 498 (44.9) 161 (6
IDU  steady sexual partnerc 167 (15.1) 110 (4
Casual sexual partnerc 428 (38.6) 49 (2
Commercial sexc 25 (2.3) 60 (2
Condom usec (last sexual intercourse)
Steady partnerd 200 (40.4) 44 (2
Casual partnerd 333 (78.5) 33 (6
Clientd 22 (88.0) 53 (8
DU, injecting drug users; OR, odds ratio; 95%CI, 95% conﬁdence interval.
a Chi-square tests.
b Factors associated with being female after adjustment for age, years of injection and 
c Last 6 months.
d Among those with steady partners, casual partners, and clients, respectively.iables.
injection, female were more likely than male to report sexual risks
behaviours such as a higher prevalence of sexual steady partners
(odds ratio [OR] = 2.62; 95% conﬁdence interval [95%CI]: 1.93–3.56),
IDU sexual steady partners (OR = 4,85; 95%CI: 3.54–6.63), and com-
mercial sex (OR = 15,2; 95%CI: 9.14–25.2) (Table 2).
Differences by gender in sexual risk behaviour were simi-
lar among immigrants than among the entire sample. Regarding
injecting risk behaviours, a greater proportion of immigrant men
(compared to immigrant women) reported to have practised indi-
rect sharing (OR = 0.49; 95%CI: 0.28–0.84) (Table 3).
The self-reported prevalence of syphilis (5.5% versus 2.5%),
genital warts (13.6% versus 3.4%), herpes (3.8% versus 1.5%) and
Chlamydia (3.0% versus 0.4%) was  higher among women. The preva-
lence of HIV in oral ﬂuid samples was  higher among women than
among men  (38.7% vs. 31.5%, p = 0.031). Contrarily, HCV prevalence
was higher among male in comparison to female IDU (73.6% vs.
67.4%, p = 0.05). After controlling for age, immigrant status and
years of injection, female were more likely than male to self-report
syphilis (OR = 2.08; 95%CI: 1.02–4.25), genital warts (OR = 4.04;
95%CI: 2.41–6.77), herpes (OR = 2.5; 95%CI: 1.08–5.82), and Chlamy-
dia (OR = 6.9; 95%CI: 1.88–25.9) (Table 4).Clearly differences were seen in the prevalence of HIV among
female IDU who reported having exchange sex for money or drugs
compared to the other group of women (53.3% versus 33.3%)
(Fig. 1).
Un (%) p-valuea ORb (95%CI)
5.5) 0.104 0.20 (0.89–1.62)
7.9) 0.470 1.11 (0.76–1.63)
2.9) 0.069 1.29 (0.90–1.84)
7.8) 0.892 0.96 (0.72–1.29)
7.0) 0.176 0.80 (0.59–1.07)
8.2) <0.0001 2.62 (1.93–3.56)
6.6) <0.0001 4.85 (3.54–6.63)
0.8) <0.0001 0.41 (0.29–0.58)
5.5) <0.0001 15.2 (9.14–25.2)
7.3) 0.003 0.57 (0.38–0.85)
7.3) 0.076 0.61 (0.32–1.17)
8.3) 1.000 1.57 (0.32–7.78)
immigrant status.
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Table  3
Comparison of risk behaviours by gender among immigrants IDU (n = 557).
ImmigrantMale IDUn (%) ImmigrantFemale IDUn (%) p-valuea ORb (95%CI)
Ever sharing syringes 203 (41.2) 31 (49.2) 0.762 1.36 (0.78–2.35)
Accepted syringesc 87 (17.7) 13 (21.0) 0.476 1.01 (0.50–2.03)
Passed on syringesc 87 (18.4) 16 (25.8) 0.173 1.26 (0.66–2.41)
Front/backloadingc 234 (49.7) 34 (54.8) 0.645 1.14 (0.66–1.96)
Sharing other injecting equipmentc 267 (56.6) 26 (41.9) 0.029 0.49 (0.28–0.84)
Steady sexual partnerc 246 (49.9) 39 (61.9) <0.0001 1.46 (0.85–2.53)
IDU  steady sexual partnerc 80 (16.3) 32 (50.8) <0.0001 5.00 (2.86–8.76)
Casual sexual partnerc 194 (39.3) 13 (20.6) 0.004 0.41 (0.21–0.78)
Commercial sexc 15 (3.0) 14 (22.2) <0.0001 8.92 (4.04–19.7)
Condom usec (last sexual intercourse)
Steady partnerd 92 (37.7) 9 (23.1) 0.008 0.54 (0.24–1.19)
Casual partnerd 154 (80.6) 8 (61.5) 0.147 0.42 (0.13–1.39)
Clientd 13 (86.7) 14 (100) 0.483 – –
IDU, injecting drug users; OR, odds ratio; 95%CI, 95% conﬁdence interval.
a Chi-square tests.
b Factors associated with being female after adjustment for age and years of injection.
c Last 6 months.
d Among those with steady partners, casual partners, and clients, respectively.
Table 4
Self-reported sexually transmitted infections and HCV/HIV prevalences in oral ﬂuid samples by gender.
Male IDUn (%) Female IDUn (%) p-valuea ORb (95%CI)
Diagnosis of syphilis 28 (2.5) 13 (5.5) 0.016 2.08 (1.02–4.25)
Diagnosis of gonorrhoea 44 (4.0) 8 (3.4) 0.660 0.78 (0.34–1.74)
Diagnosis of genital warts 37 (3.4) 32 (13.6) <0.0001 4.04 (2.41–6.77)
Diagnosis of genital or anal herpes 16 (1.5) 9 (3.8) 0.028 2.50 (1.08–5.82)
Diagnosis of Chlamydia 4 (0.4) 7 (3.0) 0.001 6.98 (1.88–25.9)
Diagnosis of hepatitis B 229 (21.1) 46 (19.7) 0.630 0.88 (0.61–1.28)
HIV  positive (oral ﬂuid samples) 810 (31.5) 159 (38.7) 0.031 1.26 (0.92–1.72)
HCV  positive (oral ﬂuid samples) 347 (73.6) 91 (67.4) 0.053 0.83 (0.60–1.14)
I an immunodeﬁciency virus; HCV: hepatitis C virus.
 and immigrant status.
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iscussion
This study examined gender differences in HIV risk behaviours,
IV and HCV prevalence among IDU recruited in harm reduction
entres. In general, the study demonstrated differences between
ale and female IDU with regard to sexual risk behaviours, but
ailed to ﬁnd differences related to injecting risk behaviours.
As in previous studies conducted in the USA, Europe and other
eveloping and transitional countries,4,15,23 female had higher
ates of sexual risk behaviours than male IDU. In particular, women
ere more likely than men  to have an IDU steady partner and
o report unprotected sex with these partners. In general among
his population, studies have found that long-term relationships
nd involvement with a partner are not perceived as high risk.24
 recent qualitative study which explored narratives about expe-
ience of preventing sexual transmission of HIV among IDU and
heir sexual partners showed the level of trust and commitment to
e one of the main factors for not using condoms.25
Consistent with studies in different European cities,15,26 a
reater proportion of female IDU had exchanged sex for money or
rugs in the last 6 months, and HIV prevalence was  more than 50%
mong this group. These groups of women are at heightened risk
f sexually acquired HIV from exposure to different sexual risk fac-
ors such as multiple sexual partners and limited condom use with
hem.1,27 Moreover, they are also exposed to environmental risks
rom the circumstances under which sex work often takes place,
uch as higher threats of violence and social marginalization.28,29arm reduction projects should be able to more effectively address
ex work related vulnerabilities, taking into account that not all
emales who inject drugs and engage in sex work will necessar-
ly identify as an IDU. This is particularly important where these
Fig. 1. HIV and HCV infections by sexual risk characteristics (last 6 months) among
female IDU.
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omen may  not see themselves as vulnerable to particular risks
ecause of their lack of identiﬁcation with these risk groups and
herefore may  be left out of targeted interventions.
In contrast to differences in sexual risk behaviours between men
nd women, there were no differences in drug-using behaviours
mong the overall sample of injectors. Although some studies in
ew York and England have found that female IDU are more likely
o share needles and equipment than male IDU,30,31 others ﬁnd no
ssociation between gender and high-risk injection practices.9,32 It
eems that patterns of needle sharing are often different between
en  and women; for example, female IDU are more likely than
ales to share needles with a sex partner who injects, and males
ith close friends.2,33,34
Gender differences in sexual risk behaviours were conﬁrmed
mong the subgroup of migrant IDU, in which female IDU face
 higher risk of sexual HIV infection than male IDU. In contrast,
he prevalence of indirect sharing among female immigrant IDU
as lower than among male immigrant IDU. Future studies about
he use of drugs according to different countries of origin would
e interesting for the development of educational, social, preven-
ive and health care strategies that are culturally adapted to this
eterogeneous group, in particular among women.
Another issue distinguishing between female and male IDU was
he prevalence of STI. A previous survey conducted in Catalonia
n a similar group of IDU conﬁrmed the higher prevalence of STI
bserved in female, compared to male IDU. In particular, preva-
ences of Chlamydia trachomatis and/or Neisseria gonorrhoea were
.8% and 2.0%, respectively.22 Apart from being an indicator of
nprotected sex, STI are important cofactors in the transmission
nd acquisition of HIV infection, thus control of one may  have ben-
ﬁcial effects on the control of the other.35 Sexual and reproductive
ealth services should be better incorporated into harm reduction
nd drug treatment services.
As in previous studies conducted in Spain,14,17 HIV prevalence
as higher among female IDUS. Although the higher HIV preva-
ence in female IDU may  be explained in part by biological factors
uch as a greater mucous membrane exposure during sex,36 the
igher HCV prevalence among male in comparison to female IDU,
n infection which is not commonly transmitted sexually, conﬁrms
hat sexual transmission of HIV could be relevant among female
DU. The ﬁndings are consistent with data available in other Euro-
ean countries from IDU mostly in drug treatment centres or other
rug services.12 A recent systematic review to assess differences
n HIV prevalence among female and male IDU in high seropreva-
ence areas showed that in the studies with a higher HIV prevalence
mong female compared to male, the authors suggested that sexual
ransmission was the reason for the difference.37 After adjustment
y immigrant status, age and years of injection, differences among
IV prevalence by gender were not signiﬁcant. Further analysis
aking into account the inﬂuence of migration will be necessary to
xplore those factors that may  increase HIV risk among female IDU.
The results of this study should be interpreted in light of the
ollowing limitations. This was a convenience sample of IDU from
arm reduction centres, which means that results may  not be gen-
ralizable to other IDU populations in Catalonia. Moreover, the
tudy sampled IDU who accessed services at harm reduction cen-
res (18.3% of the estimated number of IDUs who visited these
entres). No information was available on the injectors that were
ot approached by these centres. The second limitation concerns
he validity of data, since the prevalence of some risk behaviours
nd/or self-reported STI could be underestimated. In this sense,
ata collectors attempted to create an anonymous atmosphere for
he interviews and used simple and understandable language. Also,
esearch has demonstrated that self-reported risk behaviours are
alid and not inﬂuenced by social desirability bias.38 In addition,
lthough women may  be underrepresented in these centres, the013;27(4):338–343
present study has accessed an impressive number of female IDU
who tend to be a more “hidden” group than male IDU.
In conclusion, female IDU in Catalonia face gender-speciﬁc risks
for HIV infection. They are more likely than their male counterparts
to have a sexual partner who inject drugs and these relationships
may  leave the women in particularly vulnerable positions because
they are dependent upon these men  and are therefore potentially
in a subordinate position and less capable of negotiating safe sex
and injection behaviours. Interventions focusing on the sexual part-
nership appear to be a necessity for understanding fundamental
questions of harm reduction relative to prevention, since the use
of drugs is common within couples. It is common for female IDU
to engage in sex work, adding a further element which increases
their vulnerability to HIV infection. Taking into consideration that
research suggests that the provision of enhanced harm reduction
services for women can increase uptake and improve the out-
comes of these interventions,13,39 gender-sensitive approaches to
HIV prevention should be integrated in these centres in Catalonia,
especially for those engaging in sex work. Finally, additional studies
are needed to analyse in-depth these speciﬁc risk factors for women
in order to develop appropriate preventive and health education
programs.
What is known about this topic?
Regarding HIV infection, gender has emerged as an impor-
tant factor in both injection related and sexual risk taking in
IDU in different parts of the world, with female IDU more likely
than males to take risks that may lead to HIV infection. In Spain,
previous studies have pointed to a higher HIV prevalence and
incidence among female than male IDU. An understanding of
these differences will have major implications for designing
preventive programmes and interventions.
What does this study add to the literature?
The higher prevalence of HIV and sexual risk behaviours
among female IDU in relation to men, together with a lower
prevalence of HCV, suggests that sexual transmission of HIV is
important among this group. Prevention programs tailored to
IDU should be culturally adapted and respond to the speciﬁc
needs of female IDU, especially for those engaging in sex work.
Sexual and reproductive health should be better incorporated
into harm reduction programs.
Authors’ contributions
C. Folch and J. Casabona contributed to the conception and
design of the study. C. Folch analyzed the data and wrote the
manuscript. A. Espelt contributed to data management. X. Majó,
M.T. Brugal, and M.  Meron˜o collaborated in the questionnaire and
protocol development. M.  Meron˜o coordinated the study imple-
mentation and data collection. V. González contributed to the
laboratory analysis. C. Folch wrote the ﬁrst draft of the paper, which
was revised with contributions from all authors.
Funding
The study was  supported by the following: Direcció General
de Salut Pública, Departament de Salut, Generalitat de Catalunya;
Subdirecció General de Drogodependències, Departament de Salut,
Generalitat de Catalunya; Agència de Gestió d’Ajuts Universi-
taris i de Recerca – AGAUR (2005/SGR/00505), Departament
anit. 2
d
d
C
A
t
S
A
A
C
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3C. Folch et al. / Gac S
’Universitats, Recerca i Societat de la Informació, de la Generalitat
e Catalunya; and Red de Trastornos Adictivos [RD06/0001/1018].
onﬂict of interest
None.
cknowledgements
The authors thank all interviewers, participants and the cen-
res who have collaborated in this study: Àmbit Prevenció;
APS, Baluard, “El Local” Sant Adrià; AEC-Gris Hospitalet/PIGAD;
saupa’m Badalona i Santa Coloma; CAS Reus, AIDE Terrassa,
lba Terrassa, Arrels Lleida; Creu Roja Constantí, IAS Girona,
ADO Vic.
eferences
1. Silva VN, d’Oliveira AF, Mesquita F. Vulnerability to HIV among female injecting
drug users. Rev Saude Publica. 2007;41 (Suppl. 2):22–30.
2. Cleland CM,  Des Jarlais DC, Perlis TE, et al. HIV risk behaviors among female IDUs
in  developing and transitional countries. BMC  Public Health. 2007;7:271.
3. Booth RE. Gender differences in high-risk sex behaviours among heterosexual
drug injectors and crack smokers. Am J Drug Alcohol Abuse. 1995;21:419–32.
4. Dorman A, Keenan E, Schuttler C, et al. HIV risk behaviour in Irish intravenous
drug users. Ir J Med  Sci. 1997;166:235–8.
5. Magnus M,  Kuo I, Phillips G, et al. Differing HIV risks and prevention needs among
men  and women  injection drug users (IDU) in the District of Columbia. J Urban
Health. 2012;90:157–66.
6. Absalon J, Fuller CM,  Ompad DC, et al. Gender differences in sexual behaviors,
sexual partnerships, and HIV among drug users in New York City. AIDS Behav.
2006;10:707–15.
7. Cintra AM,  Caiaffa WT,  Mingoti SA, et al. Characteristics of male and female
injecting drug users of the AjUDE-Brasil II Project. Cad Saude Publica.
2006;22:791–802.
8. Gollub EL, Rey D, Obadia Y, et al. Gender differences in risk behaviors among
HIV+ persons with an IDU history. The link between partner characteristics and
women’s higher drug-sex risks. The Manif 2000 Study Group. Sex Transm Dis.
1998;25:483–8.
9. Riehman KS, Kral AH, Anderson R, et al. Sexual relationships, secondary syringe
exchange, and gender differences in HIV risk among drug injectors. J Urban
Health. 2004;81:249–59.
0. Barrio G, De la Fuente L, Toro C, et al. Prevalence of HIV infection among young
adult injecting and non-injecting heroin users in Spain in the era of harm reduc-
tion programmes: gender differences and other related factors. Epidemiol Infect.
2007;135:592–603.
1. De Boni R, Pechansky R, Van Diernen L, et al. Diferenc¸ as entre fatores de risco
para infecc¸ ão pelo HIV em UDI do Rio de Janeiro e Porto Alegre. Rev Psiquiatr
Clín. 2005;32:5–9.
2. Strathdee SA, Galai N, Safaiean M,  et al. Sex differences in risk factors for HIV
seroconversion among injection drug users: a 10-year perspective. Arch Intern
Med. 2001;161:1281–8.
3. Pinkham S, Stoicescu C, Myers B. Developing effective health interven-
tions for women  who  inject drugs: key areas and recommendations for
program development and policy. Adv Preve Med. 2012;2012:269123,
http://dx.doi.org/10.1155/2012/269123.4. European Monitoring Centre for Drugs and Drug Addiction. Annual report 2006.
Selected issue 2: a gender perspective on drug use and responding to drug
problems. Luxemburg: Publications Ofﬁce of the European Union; 2006.
5. Estébanez PE, Russell NK, Aguilar MD,  et al. Women, drugs and HIV/AIDS: results
of a multicentre European study. Int J Epidemiol. 2000;29:734–43.
3
3013;27(4):338–343 343
6. De la Fuente L, Bravo MJ, Barrio G, et al. Lessons from the history of the
human immunodeﬁciency virus/acquired immunodeﬁciency syndrome epi-
demic among Spanish drug injectors. Clin Infect Dis. 2003;37 (Suppl. 5):S410–5.
7. Hurtado Navarro I, Alastrue I, Del Amo J, et al. Differences between women
and men  in serial HIV prevalence and incidence trends. Eur J Epidemiol.
2008;23:435–40.
8. Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i
Sida  de Catalunya (CEEISCAT). SIVES 2010: Sistema Integrado de Vigilancia Epi-
demiológica del SIDA/VIH/ITS en Catalunya (SIVES): informe bianual. Barcelona:
Generalitat de Catalunya, Departament de Salut; 2011. Documento técnico
CEEISCAT, 2010.
9. World Health Organization. Multy-city study on drug injecting and risk of HIV
infection. Programme on substance abuse – ﬁnal report. Geneva: WHO; 1994.
0. Chohan BH, Lavreys L, Mandaliya KN, et al. Validation of a modiﬁed commer-
cial enzyme-linked immunoassay for detection of human immunodeﬁciency
virus type 1 immunoglobulin G antibodies in saliva. Clin Diagn Lab Immunol.
2001;8:346–8.
1. Judd A, Parry J, Hickman M,  et al. Evaluation of a modiﬁed commercial assay in
detecting antibody to hepatitis C virus in oral ﬂuids and dried blood spots. J Med
Virol. 2003;71:49–55.
2. Folch C, Casabona J, Brugal MT,  et al. Sexually transmitted infections and sexual
practices among injecting drug users in harm reduction centers in Catalonia. Eur
Addict Res. 2011;17:271–8.
3. Brooks A, Meade CS, Potter JS, et al. Gender differences in the rates and correlates
of HIV risk behaviors among drug abusers. Subst Use Misuse. 2010;45:2444–69.
4. Bogart LM, Kral AH, Scott A, et al. Sexual risk among injection drug users
recruited from syringe exchange programs in California. Sex Transm Dis.
2005;32:27–34.
5. Uuskula A, Abel-Ollo K, Markina A, et al. Condom use and partnership intimacy
among drug injectors and their sexual partners in Estonia. Sex Transm Infect.
2012;88:58–62.
6. Benotsch EG, Somlai AM,  Pinkerton SD, et al. Drug use and sexual risk behaviours
among female Russian IDUs who  exchange sex for money or drugs. Int J STD AIDS.
2004;15:343–7.
7. Platt L, Rhodes T, Judd A, et al. Effects of sex work on the prevalence of
syphilis among injection drug users in 3 Russian cities. Am J Public Health.
2007;97:478–85.
8. Azim T, Chowdhury EI, Reza M,  et al. Vulnerability to HIV infection among sex
worker and non-sex worker female injecting drug users in Dhaka, Bangladesh:
evidence from the baseline survey of a cohort study. Harm Reduct J. 2006;3:33.
9. Blankenship KM, Koester S. Criminal law, policing policy, and HIV  risk in female
street sex workers and injection drug users. J Law Med  Ethics. 2002;30:548–59.
0. Frajzyngier V, Neaigus A, Gyarmathy VA, et al. Gender differences in injec-
tion risk behaviors at the ﬁrst injection episode. Drug Alcohol Depend.
2007;89:145–52.
1. Bennett GA, Velleman RD, Barter G, et al. Gender differences in sharing injecting
equipment by drug users in England. AIDS Care. 2000;12:77–87.
2. Sherman SG, Latkin CA, Gielen AC. Social factors related to syringe sharing among
injecting partners: a focus on gender. Subst Use Misuse. 2001;36:2113–36.
3. Barnard MA.  Needle sharing in context: patterns of sharing among men and
women  injectors and HIV risks. Addiction. 1993;88:805–12.
4. Freeman RC, Rodríguez GM,  French JF. A comparison of male and female intra-
venous drug users’ risk behaviors for HIV infection. Am J Drug Alcohol Abuse.
1994;20:129–57.
5. Steen R, Wi  TE, Kamali A, et al. Control of sexually transmitted infections and pre-
vention of HIV transmission: mending a fractured paradigm. Bull World Health
Organ. 2009;87:858–65.
6. Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science.
2005;308:1582–3.
7. Des Jarlais DC, Feelemyer JP, Modi SN, et al. Are females who inject drugs
at higher risk for HIV infection than males who inject drugs? An interna-
tional systematic review of high seroprevalence areas. Drug Alcohol Depend.
2012;124:95–107.8. Goldstein MF, Friedman SR, Neaigus A, et al. Self-reports of HIV risk behavior by
injecting drug users: are they reliable? Addiction. 1995;90:1097–104.
9. Ashley OS, Marsden ME,  Brady TM.  Effectiveness of substance abuse treat-
ment programming for women: a review. Am J Drug Alcohol Abuse. 2003;29:
19–53.
